© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 22, 1836-1840,
November 15, 2000
© 2000 Oxford University Press
REPORT |
Prevention of N-Methyl-N-Nitrosourea-Induced Mammary Carcinogenesis in Rats by 1
-Hydroxyvitamin D5
Affiliations of authors: R. Mehta, M. Hawthorne, L. Uselding, K. Christov, R. Mehta (Department of Surgical Oncology, College of Medicine), D. Albinescu, R. Moriarty (Department of Chemistry, College of Arts and Sciences), University of Illinois, Chicago.
Correspondence to: Rajendra Mehta, Ph.D., Department of Surgical Oncology, College of Medicine, 840 S. Wood St. (M/C820), Chicago, IL 60612 (e-mail: raju{at}uic.edu).
Background: Although the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D3, is a potent cell-differentiating agent, its use in cancer prevention or therapy is precluded because it induces excessive blood calcium levels (hypercalcemia). However, less calcemic or noncalcemic synthetic analogues of vitamin D3 are poorly effective against mammary carcinogenesis. We synthesized an analogue of vitamin D5, 1
-hydroxy-24-ethylcholecalciferol (1-hydroxyvitamin D5), which was less calcemic than 1,25-dihydroxyvitamin D3 and prevented the development of precancerous lesions in mammary glands. Here, we evaluate its efficacy in an experimental rat mammary carcinogenesis model. Methods: Sprague-Dawley rats were treated with 1-hydroxyvitamin D5 beginning 2 weeks before carcinogen treatment. Animals received an intravenous injection of N-methyl-N-nitrosourea at 80 days of age and continued to receive dietary 1-hydroxyvitamin D5 for an additional 105 days. Tumor incidence and multiplicity were determined, and plasma concentrations of calcium and phosphorus were measured. The efficacy of 1-hydroxyvitamin D5 at different stages of carcinogenesis was determined in mouse mammary gland organ culture. All statistical tests were two-sided. Results: The tumor incidence was reduced from 80% (95% confidence interval [CI] = 51.9%–95.7%) in control rats to 53.3% (95% CI = 26.6%–78.8%) and 46.6% (95% CI = 21.3%–73.4%) in rats treated with 1-hydroxyvitamin D5 at 25 µg/kg diet and 50 µg/kg diet, respectively. The tumor multiplicity was reduced from 1.6 tumors per rat to 1.2 (95% CI for the difference = -0.45 to 1.25; P = .34) and 0.8 (95% CI for the difference = 0.14–1.46; P = .02), respectively. There was no statistically significant increase in the plasma calcium or phosphorus concentration at either dose level. The vitamin D5 analogue was effective during both the initiation and the promotion stages of mammary lesion formation in organ culture. Conclusion: Our findings indicate that 1-hydroxyvitamin D5 reduces the incidence of mammary carcinogenesis in vivo. This analogue appears to be a good candidate for further development as a chemopreventive agent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. A. HUSSAIN-HAKIMJEE and R. G. MEHTA Regulation of Steroid Receptor Expression by 1{alpha}-Hydroxyvitamin D5 in Hormone-responsive Breast Cancer Cells Anticancer Res, September 1, 2009; 29(9): 3555 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dhawan, R. Weider, and S. Christakos CCAAT Enhancer-binding Protein {alpha} Is a Molecular Target of 1,25-Dihydroxyvitamin D3 in MCF-7 Breast Cancer Cells J. Biol. Chem., January 30, 2009; 284(5): 3086 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Lee, S. Paul, N. Atalla, P. E. Thomas, X. Lin, I. Yang, B. Buckley, G. Lu, X. Zheng, Y.-R. Lou, et al. Gemini Vitamin D Analogues Inhibit Estrogen Receptor-Positive and Estrogen Receptor-Negative Mammary Tumorigenesis without Hypercalcemic Toxicity Cancer Prevention Research, November 1, 2008; 1(6): 476 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Valrance, A. H. Brunet, and J. Welsh Vitamin D Receptor-Dependent Inhibition of Mammary Tumor Growth by EB1089 and Ultraviolet Radiation in Vivo Endocrinology, October 1, 2007; 148(10): 4887 - 4894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, J. E. Manson, I-M. Lee, N. R. Cook, J. E. Buring, and S. M. Zhang Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women Arch Intern Med, May 28, 2007; 167(10): 1050 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Peng, R. Mehta, S. Wang, S. Chellappan, and R. G. Mehta Prohibitin is a novel target gene of vitamin d involved in its antiproliferative action in breast cancer cells. Cancer Res., July 15, 2006; 66(14): 7361 - 7369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Welsh Vitamin D and breast cancer: insights from animal models Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1721S - 1724S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Zinser and J. Welsh Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G Moorman and P. D Terry Consumption of dairy products and the risk of breast cancer: a review of the literature Am. J. Clinical Nutrition, July 1, 2004; 80(1): 5 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kavanaugh and J. E. Green The Use of Genetically Altered Mice for Breast Cancer Prevention Studies J. Nutr., July 1, 2003; 133(7): 2404S - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Welsh, J. A. Wietzke, G. M. Zinser, B. Byrne, K. Smith, and C. J. Narvaez Vitamin D-3 Receptor as a Target for Breast Cancer Prevention J. Nutr., July 1, 2003; 133(7): 2425S - 2433. [Abstract] [Full Text] [PDF]
|
|